Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
ESH CML 2022
It was great to speak with @jeff_sharman of @WVCancer recently to hear the interim results from a cohort of the MorningSun study, which evaluated fixed-duration SC mosunetuzumab in older/unfit patients with previously untreated #DLBCL.
Watch here: 👉
Fixed-duration SC mosunetuzumab in older patients with previously untreated DLBCL: MorningSun trial
Jeff Sharman, MD, Sarah Cannon Research Institute at Willamette Valley Cancer Institute & Research Center, Eugene, OR,...
ow.ly
Is there a way to predict and prevent therapy-related myeloid neoplasms in patients undergoing chemotherapy or radiation?💭
We spoke with @DrPinkalDesai of @WeillCornell at #ASH25 to gain valuable insight into this – watch the interview here:
👉 👈
Predicting and preventing therapy-related myeloid neoplasms
Pinkal Desai, MD, MPH, Weill Cornell Medicine, New York, NY, discusses the findings of an ongoing study on predict...
ow.ly
🚨 LAST CHANCE TO REGISTER for our Post ASH 2025 #Myeloma Highlights taking place TOMORROW 🔬
Join leading experts Dr Doris Hansen, @nishjo76 & Prof. Salomon Manier as they unpack the latest advances and discuss how these findings could influence clinical practice💡🎙️
🩸
In an interview from #ASH25, Heather Landau (@MSKCancerCenter) presents data from the first 20 pts treated in the NEXICART-2 trial, a Phase I/II dose escalation/expansion study of the BCMA-directed #CARTCell therapy NXC-201 in R/R AL #amyloidosis.
Watch now: 👉
🎥 In a recent interview, @mpdrc of @AtriumHealthWFB provides guidance on selecting between JAK inhibitors for the management of patients with #myelofibrosis.
Click here to watch:
👉 👈
#MPNsm #HemOnc
Guidance for selecting between JAK inhibitors in the frontline and second-line setting for MF
Ruben Mesa, MD, Levine Cancer Institute, Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Winston Salem, ...
ow.ly
ESH CML 2022
It was great to speak with @jeff_sharman of @WVCancer recently to hear the interim results from a cohort of the MorningSun study, which evaluated fixed-duration SC mosunetuzumab in older/unfit patients with previously untreated #DLBCL.
Watch here: 👉
Fixed-duration SC mosunetuzumab in older patients with previously untreated DLBCL: MorningSun trial
Jeff Sharman, MD, Sarah Cannon Research Institute at Willamette Valley Cancer Institute & Research Center, Eugene, OR,...
ow.ly
Is there a way to predict and prevent therapy-related myeloid neoplasms in patients undergoing chemotherapy or radiation?💭
We spoke with @DrPinkalDesai of @WeillCornell at #ASH25 to gain valuable insight into this – watch the interview here:
👉 👈
Predicting and preventing therapy-related myeloid neoplasms
Pinkal Desai, MD, MPH, Weill Cornell Medicine, New York, NY, discusses the findings of an ongoing study on predict...
ow.ly
🚨 LAST CHANCE TO REGISTER for our Post ASH 2025 #Myeloma Highlights taking place TOMORROW 🔬
Join leading experts Dr Doris Hansen, @nishjo76 & Prof. Salomon Manier as they unpack the latest advances and discuss how these findings could influence clinical practice💡🎙️
🩸
In an interview from #ASH25, Heather Landau (@MSKCancerCenter) presents data from the first 20 pts treated in the NEXICART-2 trial, a Phase I/II dose escalation/expansion study of the BCMA-directed #CARTCell therapy NXC-201 in R/R AL #amyloidosis.
Watch now: 👉
🎥 In a recent interview, @mpdrc of @AtriumHealthWFB provides guidance on selecting between JAK inhibitors for the management of patients with #myelofibrosis.
Click here to watch:
👉 👈
#MPNsm #HemOnc
Guidance for selecting between JAK inhibitors in the frontline and second-line setting for MF
Ruben Mesa, MD, Levine Cancer Institute, Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Winston Salem, ...
ow.ly
